NATURAL CAPSULES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 342.3 INR | -1.33% |
|
+6.27% | -4.85% |
| 19/03 | Natural Capsules Begins Production in First High-Speed HPMC Line | MT |
| 09/02 | Natural Capsules Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Sales 2022 | 1.35B 16.19M | Sales 2023 | 1.72B 20.66M | Capitalization | 2.76B 33.02M |
|---|---|---|---|---|---|
| Net income 2022 | 139M 1.67M | Net income 2023 | 184M 2.21M | EV / Sales 2022 | 3.54 x |
| Net Debt 2022 | 464M 5.56M | Net Debt 2023 | 900M 10.79M | EV / Sales 2023 | 2.12 x |
| P/E ratio 2022 |
23.3
x | P/E ratio 2023 |
19.8
x | Employees | 177 |
| Yield 2022 |
0.22% | Yield 2023 |
0.25% | Free-Float | 36.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.33% | ||
| 1 week | +6.27% | ||
| Current month | +12.05% | ||
| 1 month | +12.05% | ||
| 3 months | -5.27% | ||
| 6 months | -7.25% | ||
| Current year | -4.85% |
1 week
340.00
384.00
1 month
305.60384.00
Current year
295.00400.00
1 year
295.00486.00
3 years
125.10679.00
5 years
32.65679.00
10 years
32.65679.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 83 | 29/93/29 | |
| Director of Finance/CFO | - | 09/22/09 | |
Shilpa Burman
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 30/19/30 | |
| Chairman | 81 | 29/94/29 | |
| Director/Board Member | 81 | 01/11/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 342.3 | -1.33% | 5,610 |
| 29/24/29 | 346.9 | -2.31% | 4,670 |
| 26/24/26 | 355.1 | -1.43% | 11,133 |
| 25/24/25 | 360.2 | +0.18% | 12,104 |
| 24/24/24 | 359.6 | -1.10% | 34,930 |
Delayed Quote Bombay S.E., April 30, 2024 at 03:47 pm IST
More quotes
Natural Capsules Limited is an India-based hard capsule shell manufacturer, specialized in the manufacturing of vegetarian capsules. The Company's product portfolio includes capsules and steroidal active pharmaceutical ingredients (APIs). Its offerings include hard gelatin capsules, hydroxypropyl methylcellulose (HPMC) vegetarian capsules and others, including shiny capsules, sweet capsules, fast-release capsules, regulatory variants, sodium laureth sulfate (SLS) free capsules, preservative free capsules and transmissible spongiform encephalopathy (TSE) free capsules. The Company, through its subsidiary, Natural Biogenex Private Limited, is focused on manufacturing APIs such as prednisolone, betamethasone, dexamethasone, and hydrocortisone along with their derivatives. The Company exports its products to over 30 countries. It has two manufacturing facilities that are located in Bengaluru and Puducherry. It has a production capacity of around five million capsules per machine per day.
Sector
Pharmaceuticals
Calendar
17/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.85% | 37.98M | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- NATCAPSUQ6 Stock
